ip-costeffevtivenessof-2020.pdf (1.59 MB)
The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era
journal contribution
posted on 2020-03-01, 00:00 authored by A Vasudevan, Francis IpFrancis Ip, D Liew, D R Van LangenbergThe Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era
History
Journal
Inflammatory Bowel DiseasesVolume
26Issue
3Pagination
369 - 379Publisher
Oxford University PressLocation
Oxford, Eng.Publisher DOI
ISSN
1078-0998eISSN
1536-4844Language
engPublication classification
C1 Refereed article in a scholarly journalUsage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC